OneSource Specialty Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from OneSource Specialty Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹35 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than almost all Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹9 is tangible; the rest is goodwill and other intangibles, often from buying other companies. Less tangible than 97% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 94% of Healthcare companies in India.
Cash Locked Ratio
₹47For every ₹100 of sales, ₹47 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹404 from others' credit three years earlier.
More money tied up than 87% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹53Sales grew 3,572% in 3 years; of every extra ₹100 of sales, ₹53 became extra profit.
Higher than 93% of Healthcare companies in India.
Asset Productivity Ratio
+3572% / +309%In 3 years sales changed by +3572% while total assets changed by +309%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.0×Debt due within a year is covered 0.0 times by its yearly operating cash.
Lower than 87% of Healthcare companies in India.
Cash Cushion Ratio
−9%Debt, after subtracting cash, equals 9% of its market value (net debt).
Lower than 75% of Healthcare companies in India.
Tangible Assets Ratio
35%Of every ₹100 the company owns, ₹35 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than almost all Healthcare companies in India.
Tangible Net Worth Ratio
9%Of every ₹100 of net worth, ₹9 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 97% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
OneSource Specialty Pharma Limited made a loss over the last year. OneSource Specialty Pharma Limited owes ₹0.29 for every ₹1 it owns. OneSource Specialty Pharma Limited made a loss in each of the last two years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
LossOneSource Specialty Pharma Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.62The share price is 2.62 times OneSource Specialty Pharma Limited's book value per share, lower than 75% of Healthcare companies in India.
Market cap
₹15,299 CrThe total market value of all of OneSource Specialty Pharma Limited's shares at today's price (share price × number of shares), larger than 74% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹5,831 CrWhat OneSource Specialty Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹508.51Net worth divided by the number of shares. The share price of ₹1,334 is 2.6 times this, which is the P/B above.
Return on equity (ROE)
-0.8%OneSource Specialty Pharma Limited lost 0.8% of its shareholders' money over the last year, lower than 94% of Healthcare companies in India.
Owes vs Owns
0.29×OneSource Specialty Pharma Limited owes ₹0.29 for every ₹1 it owns (low), lower than 69% of Healthcare companies in India.
Dividend yield
NoneOneSource Specialty Pharma Limited does not currently pay a dividend.
Revenue growth
-2%Revenue fell 2% in the year to Mar 2026, and grew 232% a year on average over 3 years.
Profit growth
LossOneSource Specialty Pharma Limited made a loss in each of the last two years.
Profit margin
-5.2%OneSource Specialty Pharma Limited lost ₹5 for every ₹100 of revenue.
Interest cover
Not coveredOneSource Specialty Pharma Limited's operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net debtOneSource Specialty Pharma Limited had ₹1,456 Cr more debt than cash (net debt) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For OneSource Specialty Pharma Limited: ₹15,299 Cr ÷ ₹5,831 Cr (31 Mar 2026) = 2.6.
What is OneSource Specialty Pharma Limited's return on equity?
OneSource Specialty Pharma Limited lost 0.8% of its shareholders' money over the last year, lower than 94% of Healthcare companies in India.
How much does OneSource Specialty Pharma Limited owe compared with what it owns?
OneSource Specialty Pharma Limited owes ₹0.29 for every ₹1 it owns (low), lower than 69% of Healthcare companies in India.
Does OneSource Specialty Pharma Limited pay a dividend?
No. OneSource Specialty Pharma Limited does not currently pay a dividend.
Is OneSource Specialty Pharma Limited's revenue growing?
Revenue fell 2% in the year to Mar 2026, and grew 232% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.